|
EP0731636B1
(en)
*
|
1993-11-30 |
2006-01-11 |
Tanox, Inc. |
Cdn apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
|
|
US6300482B1
(en)
*
|
1995-01-03 |
2001-10-09 |
Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der |
MDKI, a novel receptor tyrosine kinase
|
|
US20060205020A1
(en)
*
|
1995-09-06 |
2006-09-14 |
Icos Corporation |
Cell-cycle checkpoint genes
|
|
US6136311A
(en)
*
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
ATE256740T1
(en)
*
|
1997-02-06 |
2004-01-15 |
Inst Genetics Llc |
HUMAN SDF-5 PROTEIN AND RELATED COMPOSITIONS
|
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
|
US20030171542A1
(en)
*
|
1997-07-03 |
2003-09-11 |
Zymogenetics, Inc. |
Mammalian secretory peptide - 9
|
|
WO1999058640A2
(en)
*
|
1998-05-11 |
1999-11-18 |
Philadelphia Health And Education Corporation |
Mct-1, a human oncogene
|
|
US20030055231A1
(en)
*
|
1998-10-28 |
2003-03-20 |
Jian Ni |
12 human secreted proteins
|
|
EP1176199B1
(en)
*
|
1999-04-26 |
2004-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Tumor suppressor gene
|
|
AU1891601A
(en)
*
|
1999-12-16 |
2001-06-25 |
Chugai Research Institute For Molecular Medicine, Inc. |
Novel human RNA helicase, helicain
|
|
US6922676B2
(en)
*
|
1999-12-30 |
2005-07-26 |
Jeffrey Alnwick |
Method and system for ordering items over the internet
|
|
US7009040B2
(en)
*
|
2003-01-21 |
2006-03-07 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
|
CA2436713A1
(en)
*
|
2000-12-08 |
2002-08-22 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
|
US20020164703A1
(en)
*
|
2000-12-21 |
2002-11-07 |
Krzysztof Pawlowski |
Card-domain containing polypeptides, encoding nucleic acids, and methods of use
|
|
US7381701B2
(en)
*
|
2001-02-15 |
2008-06-03 |
The Borad Of Trustees Of The University Of Illinois |
Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
|
|
US9096663B2
(en)
*
|
2001-02-15 |
2015-08-04 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
|
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
|
AU2002258626B2
(en)
*
|
2001-04-10 |
2007-01-18 |
Agensys, Inc. |
Nucleid acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
|
|
EP1252894A1
(en)
*
|
2001-04-26 |
2002-10-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
|
|
JP2002348254A
(en)
*
|
2001-05-24 |
2002-12-04 |
Japan Science & Technology Corp |
Nervous system tumor treatment
|
|
US20030109440A1
(en)
*
|
2001-10-03 |
2003-06-12 |
Rigel Pharmaceuticals, Incorporated |
GRB7: novel regulator of lymphocyte signaling
|
|
US20050026833A1
(en)
*
|
2001-11-08 |
2005-02-03 |
Rabbani Shafaat Ahmed |
PSP-94: use for treatment of hypercalcemia and bone metastasis
|
|
US7422862B2
(en)
*
|
2001-11-28 |
2008-09-09 |
The Burnham Institute |
Methods for identifying modulators of apoptosis
|
|
US9575070B2
(en)
*
|
2001-12-04 |
2017-02-21 |
Wayne State University |
Neoepitope detection of disease using protein arrays
|
|
US20050089896A1
(en)
*
|
2003-02-18 |
2005-04-28 |
Roy Frans V. |
Method to control tumor progression and invasiveness
|
|
US20030186241A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Ken-Shwo Dai |
Human choline/ethanolamine kinase (HCEK)-related gene variant associated with lung cancers
|
|
US20060088537A1
(en)
*
|
2002-04-11 |
2006-04-27 |
Terrett Jonathan A |
Protein involved in cancer
|
|
JP2004057003A
(en)
*
|
2002-06-03 |
2004-02-26 |
Norihiro Chano |
Rb1 gene-induced protein (rb1cc1) and gene
|
|
EP1554578A2
(en)
*
|
2002-06-11 |
2005-07-20 |
The General Hospital Corporation |
Identification of inhibitors of mitosis
|
|
US7772372B2
(en)
*
|
2002-07-04 |
2010-08-10 |
Patrys Limited |
Neoplasm specific antibodies and uses thereof
|
|
US7723018B2
(en)
*
|
2002-08-30 |
2010-05-25 |
Rigel Pharmaceuticals, Incorporated |
Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
|
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
|
SI1546182T1
(en)
*
|
2002-09-11 |
2011-04-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
DE10248751A1
(en)
*
|
2002-10-18 |
2004-05-06 |
Berdel, Wolfgang E., Prof. Dr.med. |
Dyslocation molecules and their use
|
|
DE10254601A1
(en)
*
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Gene products differentially expressed in tumors and their use
|
|
CN1209372C
(en)
*
|
2002-11-27 |
2005-07-06 |
上海市肿瘤研究所 |
Human tumor relative gene CT120 in human 17p 13.3 area and coding protein thereof
|
|
WO2004073656A2
(en)
|
2003-02-20 |
2004-09-02 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US20080025989A1
(en)
*
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US7462704B2
(en)
*
|
2003-02-27 |
2008-12-09 |
Shanghai Genomics, Inc |
Tumor marker and its use
|
|
US7488713B2
(en)
*
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
|
WO2005039382A2
(en)
*
|
2003-06-24 |
2005-05-06 |
Genomic Health |
Prediction of likelihood of cancer recurrence
|
|
US8198020B2
(en)
*
|
2003-08-22 |
2012-06-12 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
WO2005094420A2
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
|
US8759317B2
(en)
|
2004-03-18 |
2014-06-24 |
University Of South Florida |
Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
|
|
AU2005244154C1
(en)
*
|
2004-04-28 |
2010-07-01 |
Fibrogen, Inc. |
Treatments for pancreatic cancer
|
|
JP2007536274A
(en)
*
|
2004-05-07 |
2007-12-13 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア |
Endothelial cell apoptosis induced by fibrinogen γ chain C-terminal fragment
|
|
EP2484365B1
(en)
*
|
2004-06-04 |
2013-10-02 |
The Scripps Research Institute |
Compositions and method for treatment of neovascular diseases
|
|
CA2579547A1
(en)
*
|
2004-09-09 |
2006-03-16 |
Auckland Uniservices Limited |
Novel peptides and methods for the treatment of inflammatory disease
|
|
US8741578B2
(en)
*
|
2004-11-02 |
2014-06-03 |
The Regents Of The University Of California |
Methods of detecting chronic lymphocytic leukemia with Hsp90 and ZAP-70
|
|
KR100664587B1
(en)
*
|
2004-12-22 |
2007-01-04 |
김현기 |
Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
|
|
JP2008527351A
(en)
*
|
2005-01-06 |
2008-07-24 |
イースタン バージニア メディカル スクール |
Apolipoprotein A-II isoform as a biomarker for prostate cancer
|
|
DK2325305T3
(en)
*
|
2005-02-25 |
2014-03-03 |
Oncotherapy Science Inc |
Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
|
|
CA2597255C
(en)
*
|
2005-03-03 |
2014-05-27 |
Chemcom S.A. |
Natural ligand of g protein coupled receptor rcc356 and uses thereof
|
|
AU2006220825A1
(en)
*
|
2005-03-07 |
2006-09-14 |
Genentech, Inc. |
Methods and compositions for modulating TWEAK and FN14 activity
|
|
WO2006095897A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Takeda Pharmaceutical Company Limited |
Screening method
|
|
EP1894574A4
(en)
*
|
2005-04-18 |
2011-05-18 |
Univ Mie |
ANTICANCER AGENT COMPRISING A PROTEIN C INHIBITOR
|
|
ES2477765T3
(en)
|
2005-04-19 |
2014-07-17 |
Seattle Genetics, Inc. |
Binding agents to humanized anti-cd70 and their uses
|
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
|
EP1739092A1
(en)
*
|
2005-06-28 |
2007-01-03 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Peptidic antagonists of class III semaphorins/neuropilins complexes
|
|
CN100347307C
(en)
*
|
2005-07-25 |
2007-11-07 |
中国人民解放军第四军医大学 |
Recombination chimeric molecule Cb1-Grb2(SH2)-RING eukaryotic expression plasmid and antitumor genetic medicine use
|
|
EP1946113A4
(en)
*
|
2005-08-22 |
2010-03-10 |
Dana Farber Cancer Inst Inc |
MITOCHONDRIAL LOCATION OF MUC1
|
|
WO2007022635A2
(en)
*
|
2005-08-25 |
2007-03-01 |
The University Of Manitoba |
Methods of attenuating prostate tumor growth by insulin-like growth factor binding protein-3 (igfbp-3)
|
|
DE102005041616B4
(en)
*
|
2005-09-01 |
2011-03-17 |
Johannes-Gutenberg-Universität Mainz |
Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
|
|
US20070161060A1
(en)
*
|
2005-09-07 |
2007-07-12 |
Anderson Richard A |
Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin
|
|
WO2007037245A1
(en)
*
|
2005-09-29 |
2007-04-05 |
Shionogi & Co., Ltd. |
Polypeptide having anti-angiogenic activity
|
|
US9486408B2
(en)
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
|
WO2007071410A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Sentoclone Ab |
Method for treating urinary bladder cancer
|
|
US7723043B2
(en)
*
|
2006-01-04 |
2010-05-25 |
Picobella, Lp |
Methods for screening for prostate cancer
|
|
US20090035310A1
(en)
*
|
2006-02-28 |
2009-02-05 |
Wayne State University |
Cancer treatment
|
|
GB0607354D0
(en)
*
|
2006-04-12 |
2006-05-24 |
Bioinvent Int Ab |
Agent, Composition And Method
|
|
WO2007130672A2
(en)
*
|
2006-05-05 |
2007-11-15 |
University Of South Florida |
Urodilatin cancer treatment
|
|
WO2007133654A2
(en)
*
|
2006-05-10 |
2007-11-22 |
The Trustees Of Columbia University In The City Of New York |
Two pore channels as regulators of proliferation in cancer
|
|
US9127293B2
(en)
*
|
2006-07-26 |
2015-09-08 |
The University Of Chicago |
Receptor-mediated delivery: compositions and methods
|
|
US7825092B2
(en)
*
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
|
KR20090064378A
(en)
*
|
2006-08-10 |
2009-06-18 |
온코세라피 사이언스 가부시키가이샤 |
Breast Cancer Related Genes and Polypeptides
|
|
US20100111941A1
(en)
*
|
2006-09-13 |
2010-05-06 |
Steven Deitcher |
Methods for treating cancer
|
|
NZ576852A
(en)
|
2006-10-26 |
2012-02-24 |
Genentech Inc |
Genetic variations (in the phosphatidylinositol 3-kinase regulatory subunit 1 pik3r1 protein) associated with tumors and method of testing for
|
|
KR20090088879A
(en)
*
|
2006-11-13 |
2009-08-20 |
에프. 호프만-라 로슈 아게 |
Cancer Disease Control Antibodies
|
|
US8420591B2
(en)
*
|
2006-12-08 |
2013-04-16 |
Dana-Farber Cancer Institute, Inc. |
MUC1 and galectin-3
|
|
US8003761B2
(en)
|
2007-01-23 |
2011-08-23 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
|
US20080200387A1
(en)
*
|
2007-02-15 |
2008-08-21 |
Hua-Lin Wu |
Anti-angiogenic protein, composition and use thereof
|
|
US7816082B2
(en)
*
|
2007-03-06 |
2010-10-19 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods of identifying pancreatic cancer cells
|
|
GB0709092D0
(en)
*
|
2007-05-11 |
2007-06-20 |
Borrebaeck Carl |
Diagnosis and method of disease
|
|
US8664359B2
(en)
*
|
2007-06-03 |
2014-03-04 |
Oncotx, Inc. |
Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets
|
|
CN103360466B
(en)
*
|
2007-07-27 |
2016-08-03 |
伊玛提克斯生物技术有限公司 |
Antitumor related peptides and relevant anti-cancer vaccine compositions
|
|
CN101842116A
(en)
*
|
2007-08-28 |
2010-09-22 |
比奥根艾迪克Ma公司 |
Compositions binding multiple epitopes of IGF-1R
|
|
US20090123439A1
(en)
*
|
2007-11-09 |
2009-05-14 |
The Jackson Laboratory |
Diagnostic and prognosis methods for cancer stem cells
|
|
KR20100111697A
(en)
*
|
2007-12-17 |
2010-10-15 |
인썸 |
Use of fzc18-containing collagen 18 polypeptides for the treatment, diagnosis and outcome prediction of diseases
|
|
WO2009100127A2
(en)
*
|
2008-02-05 |
2009-08-13 |
The Regents Of The University Of California |
Isolated brca1 peptides and method of use
|
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
US20110052494A1
(en)
*
|
2008-07-21 |
2011-03-03 |
Tweten Rodney K |
H-antigen binding polypeptides and methods of use
|
|
US8182809B1
(en)
*
|
2008-09-08 |
2012-05-22 |
University Of Washington |
Methods for treating cancer by inhibiting MIC shedding
|
|
AU2009295842A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Proteosys Ag |
Novel antibodies recognizing native annexin A3
|
|
US8394924B2
(en)
*
|
2008-10-23 |
2013-03-12 |
Massachusetts Institute Of Technology |
Directed engagement of activating Fc receptors
|
|
US8722856B2
(en)
*
|
2008-10-28 |
2014-05-13 |
National University Corporation Hokkaido University |
Anti-MUC1 antibody
|
|
WO2010073694A1
(en)
*
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
Diagnosis of treatment of cancer using anti-tm4sf20 antibody
|
|
WO2010115118A2
(en)
*
|
2009-04-03 |
2010-10-07 |
Antigenics, Inc. |
Methods for preparing and using multichaperone-antigen complexes
|
|
EP2416804B1
(en)
|
2009-04-08 |
2017-03-01 |
Faulstich, Heinz, Dr. |
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
|
|
RU2561041C2
(en)
*
|
2009-05-06 |
2015-08-20 |
Биотест Аг |
Applications of immunoconjugates with cd138 as target
|
|
EP2433124B1
(en)
*
|
2009-05-19 |
2017-03-01 |
Vivia Biotech S.L. |
Methods for providing personalized medicine tests ex vivo for hematological neoplasms
|
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
|
WO2011020090A2
(en)
*
|
2009-08-14 |
2011-02-17 |
Case Western Reserve University |
Compositions and methods for treating cancer
|
|
GB0921873D0
(en)
|
2009-12-15 |
2010-01-27 |
Cytosystems Ltd |
Assay
|
|
US8735342B2
(en)
|
2010-01-27 |
2014-05-27 |
Neumedicines, Inc. |
Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
|
|
AU2011213678B2
(en)
|
2010-02-04 |
2015-01-29 |
Eisai Inc. |
Chlorotoxin polypeptides and conjugates and uses thereof
|
|
ES2601182T3
(en)
|
2010-05-11 |
2017-02-14 |
Fred Hutchinson Cancer Research Center |
Chlorotoxin variants, conjugates and methods for their use
|
|
CN103003695B
(en)
*
|
2010-07-15 |
2016-08-17 |
积水医疗株式会社 |
The detection method of malignant cell
|
|
GB201103631D0
(en)
*
|
2011-03-03 |
2011-04-13 |
Univ Leeds |
Identification of candidate therapeutics
|
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
|
PH12013502201A1
(en)
*
|
2011-04-25 |
2014-01-13 |
Daiichi Sankyo Co Ltd |
Anti-b7-h3 antibody
|
|
EP2524929A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sanofi |
Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
|
|
UA112434C2
(en)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
ANTIGENCY BINDING SPECIFICALLY Binds to ALL
|
|
AU2012264890C1
(en)
*
|
2011-05-27 |
2016-03-10 |
Glaxo Group Limited |
BCMA (CD269/TNFRSF17) -binding proteins
|
|
US8753640B2
(en)
|
2011-05-31 |
2014-06-17 |
University Of Washington Through Its Center For Commercialization |
MIC-binding antibodies and methods of use thereof
|
|
MX340498B
(en)
|
2011-06-30 |
2016-07-11 |
Chugai Pharmaceutical Co Ltd |
HETERODIMERIZED POLYPEPTIDE.
|
|
CN102268089A
(en)
*
|
2011-07-05 |
2011-12-07 |
上海交通大学 |
AGR2 (Anterior Gradient-2) blocking antibody and application thereof
|
|
EP2772268B8
(en)
|
2011-10-28 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
|
US8871908B2
(en)
*
|
2011-11-11 |
2014-10-28 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
DK2808028T3
(en)
*
|
2011-11-21 |
2019-10-07 |
Univ Tsukuba |
ACTIVITY MODULATOR, MEDICAL AGENT COMPREHENSIVE SAME, USE OF MICE WITH CD300A GEN deficiency and ANTI-CD300A ANTIBODY
|
|
CN104302324A
(en)
|
2011-12-08 |
2015-01-21 |
生物测试股份公司 |
Uses of immunoconjugates targeting cd138
|
|
ITRM20120060A1
(en)
*
|
2012-02-21 |
2013-08-22 |
Consiglio Nazionale Ricerche |
PEPTIDES ABLE TO RELEASE THE MDM2 / MDM4 HETERODYMER AND THEIR USE IN CANCER TREATMENT.
|
|
WO2013133253A1
(en)
|
2012-03-08 |
2013-09-12 |
独立行政法人科学技術振興機構 |
Anticancer agent
|
|
RU2678127C2
(en)
|
2012-11-13 |
2019-01-23 |
Бионтех Аг |
Agents for treatment of claudin expressing cancer diseases
|
|
SG11201504600UA
(en)
|
2012-12-10 |
2015-07-30 |
Hutchinson Fred Cancer Res |
Methods for screening
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
AU2013370932B2
(en)
*
|
2012-12-24 |
2019-02-21 |
Cell Ideas Pty Ltd |
Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
|
|
JP6433297B2
(en)
|
2012-12-27 |
2018-12-05 |
中外製薬株式会社 |
Heterodimerized polypeptide
|
|
EP3831840A1
(en)
|
2013-03-15 |
2021-06-09 |
Celgene Corporation |
Modified t lymphocytes
|
|
JPWO2014208482A1
(en)
*
|
2013-06-24 |
2017-02-23 |
中外製薬株式会社 |
A therapeutic agent for non-small cell lung cancer other than adenocarcinoma comprising humanized anti-Epiregulin antibody as an active ingredient
|
|
US9879081B2
(en)
*
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
EP3708189B1
(en)
|
2013-07-05 |
2023-11-29 |
University of Washington through its Center for Commercialization |
Soluble mic neutralizing monoclonal antibody for treating cancer
|
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3096770A4
(en)
*
|
2014-01-16 |
2017-12-06 |
Rowan University |
Modulation of cellular localization of cyclin c
|
|
US10538591B2
(en)
|
2014-03-10 |
2020-01-21 |
The Brigham And Women's Hospital, Inc. |
Anti-fibulin-3 antibodies and uses thereof
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
WO2015175965A1
(en)
|
2014-05-15 |
2015-11-19 |
The Research Foundation For Suny |
Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
|
|
BR112017001821A2
(en)
|
2014-07-29 |
2017-11-21 |
Cellectis |
ror1 (ntrkr1) -specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3194432B1
(en)
*
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
|
WO2016028896A1
(en)
*
|
2014-08-19 |
2016-02-25 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
EP3189073B2
(en)
|
2014-09-04 |
2025-06-11 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
BR112017005390A2
(en)
*
|
2014-09-17 |
2017-12-12 |
Novartis Ag |
target cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
EP3215522B1
(en)
*
|
2014-11-03 |
2021-12-01 |
Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum |
T cell receptors directed against bob1 and uses thereof
|
|
US10047138B1
(en)
*
|
2014-12-03 |
2018-08-14 |
Amgen Inc. |
Fusion protein, cells expressing the fusion protein, and uses thereof
|
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN107709548B
(en)
*
|
2015-02-06 |
2022-06-28 |
新加坡国立大学 |
Methods for enhancing the efficacy of therapeutic immune cells
|
|
US10195272B2
(en)
*
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
WO2016164428A1
(en)
*
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
US11896614B2
(en)
|
2015-04-17 |
2024-02-13 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3298046B1
(en)
|
2015-05-20 |
2025-02-12 |
Cellectis |
Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
|
|
CN109476722A
(en)
*
|
2015-07-21 |
2019-03-15 |
诺华股份有限公司 |
Methods for improving the efficacy and expansion of immune cells
|
|
AU2016316033B2
(en)
*
|
2015-09-04 |
2022-03-03 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
EP3378492A4
(en)
*
|
2015-11-20 |
2019-11-13 |
Kyushu University National University Corporation |
IMMUNOREGULATOR
|
|
UA126373C2
(en)
|
2015-12-04 |
2022-09-28 |
Новартіс Аг |
COMPOSITION AND METHOD FOR IMMUNO-ONCOLOGY
|
|
AU2016366226B2
(en)
|
2015-12-09 |
2023-06-01 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of using same
|
|
RS65430B1
(en)
|
2016-03-16 |
2024-05-31 |
Amal Therapeutics Sa |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
|
|
US12048732B2
(en)
|
2016-04-15 |
2024-07-30 |
Blaze Bioscience, Inc. |
Methods of treating breast cancer
|
|
EP3507361A1
(en)
|
2016-08-30 |
2019-07-10 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use for treating viral and other infections
|
|
EP3515476B1
(en)
|
2016-09-21 |
2024-05-22 |
Amal Therapeutics SA |
Fusion comprising a cell penetrating peptide, a multiepitope and a tlr peptide agonist for treatment of cancer
|
|
US12447213B2
(en)
*
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
BR112019010131A2
(en)
|
2016-11-21 |
2019-10-08 |
Eirion Therapeutics, Inc. |
transdermal delivery of large agents
|
|
US10550183B2
(en)
|
2016-11-22 |
2020-02-04 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
EP3585431A4
(en)
|
2017-02-24 |
2020-12-16 |
MacroGenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US12275787B2
(en)
|
2017-06-21 |
2025-04-15 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), compositions and methods thereof
|
|
CN111770937A
(en)
*
|
2017-12-29 |
2020-10-13 |
希望之城 |
meditope-enable T cells
|
|
AU2019251473A1
(en)
*
|
2018-04-10 |
2020-10-22 |
Amgen Inc. |
Chimeric receptors to DLL3 and methods of use thereof
|
|
WO2019212752A1
(en)
*
|
2018-05-03 |
2019-11-07 |
University Of Utah Research Foundation |
Oca-b peptide conjugates and methods of treatment
|
|
BR112020024296A2
(en)
|
2018-08-27 |
2021-03-09 |
Regeneron Pharmaceuticals, Inc. |
METHODS FOR THE PRODUCTION OF A CONCENTRATED PROTEIN PURIFICATION INTERMEDIATE, FOR MONITORING AND CONTROL OF CRITICAL QUALITY ATTRIBUTES IN A PROTEIN PURIFICATION INTERMEDIATE AND TO MONITOR AND CONTROL THE EXCIPIENT LEVELS IN THE CULTURE AND CULTURE FLUID FLUID. PROTEIN, AND, PROTEIN PURIFICATION INTERMEDIATE
|
|
KR20210075117A
(en)
*
|
2018-10-05 |
2021-06-22 |
세인트 안나 킨더크렙스포르슝 |
Chimeric antigen receptor (CAR) group
|
|
EP3908613A4
(en)
*
|
2019-01-07 |
2022-10-19 |
Celluris Participações Ltda. |
TANDEM BISPECIFIC CAR RECEPTOR AND METHOD FOR MODULATING A TUMOR MICROENVIRONMENT
|
|
US20220273711A1
(en)
*
|
2019-05-16 |
2022-09-01 |
University Of Washington |
Ultraspecific Cell Targeting Using De Novo Designed Co-Localization Dependent Protein Switches
|
|
TWI877278B
(en)
|
2019-12-30 |
2025-03-21 |
美商思進公司 |
Methods of treating cancer with nonfucosylated anti-cd70 antibodies
|
|
CA3170706A1
(en)
*
|
2020-02-05 |
2021-08-12 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors with cd28 mutations and use thereof
|
|
WO2021168399A1
(en)
*
|
2020-02-21 |
2021-08-26 |
Regents Of The University Of Minnesota |
Novel methods for creating alpha-n-methylated polypeptides
|